Tumor suppressor gene alteration in adult acute lymphoblastic leukemia (ALL). Analysis of retinoblastoma (Rb) and p53 gene expression in lymphoblasts of patients with de novo, relapsed, or refractory ALL treated in southwest oncology group studies

Leukemia

Volumn 10, Issue 12, 1996, Pages 1901-1910

  Tsai, T ^a,b   Davalath, S ^a,b   Rankin, C ^c   Radich, J P ^c   Head, D ^d   Appelbaum, F R ^c,e,f   Boldt, D H ^a,b,g  

^a Univ of Texas Hlth Science Center ^*  (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f SW Oncol Grp Leukemia Biol Prog ^*  (United States)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

ALL; p53; Retinoblastoma (Rb) gene; Tumor suppressor genes

Indexed keywords

ASPARAGINASE; BCR ABL PROTEIN; CD34 ANTIGEN; CYTARABINE; DAUNORUBICIN; METHOTREXATE; MITOXANTRONE; PROTEIN P53; RETINOBLASTOMA PROTEIN; RIBONUCLEASE; TIOGUANINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL TRIAL; COMPARATIVE STUDY; EXON; FEMALE; GENE REPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOBLAST; MAJOR CLINICAL STUDY; MALE; ONCOLOGY; PHASE 2 CLINICAL TRIAL; POINT MUTATION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0030475858     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Hoelzer D. Treatment of acute lymphoblastic leukemia. Semin Hematol 1994; 31: 1-15.
2. Copelan EA, McGuire EA. The biology and treatment of acute lymphoblastic leukemia in adults. Blood 1995; 85: 1151-1168.
3. Hoelzer D. Acute lymphoblastic leukemia - progress in children, less in adults. New Engl J Med 1993; 329: 1343-1344.
4. Riley DJ, Lee EY-HP, Lee H-W. The retinoblastoma protein: more than a tumor suppressor. Annu Rev Cell Biol 1994; 10: 1-29.
5. Prockocimer M, Rotter V. Structure and function of p53 in normal cells and their aberrations in cancer cells. Projection on the hematologic cell lineages. Blood 1994; 84: 2391-2411.
6. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995; 86: 841-854.
7. Imamura J, Miyoshi I, Koeffler HP. p53 in hematologic malignancies. Blood 1994; 84: 2312-2321.
8. Benedict WF, Xu H-J, Hu S-X, Takahashi R. Role of the retinoblastoma gene in the initiation and progression of human cancer. J Clin Invest 1990; 85: 988-993.
9. Phillips RA, Gill RM, Zacksenhaus E, Bremner R, Jiang Z, Sopta M, Gallie BL, Hamel PA. Why don't germline mutations in RB1 predispose to leukemia? Curr Topics Microbiol Immunol 1992; 182: 485-491.
10. Schauer P, Arlin ZA, Mertelsmann R, Cirrincione C, Friedman A, Gee TS, Dowling M, Kempin S, Straus DJ, Koziner B, McKenzie S, Thaler HT, Dufour P, Little C, Dellaquilla C, Ellis S, Clarkson B. Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols. J Clin Oncol 1983; 1: 462-470.
11. Hussein KK, Dahlberg S, Head D, Waddell CC, Dabich L, Weick JK, Morrison F, Saiki JH, Metz E, Rivkin SE, Grever MR, Boldt D. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood 1989; 73: 57-63.
12. Head DR, Savage RA, Cerezo L, Craven CM, Bickers JN, Hartsock R, Hosty TA, Saiki JH, Wilson HE, Morrison FS, Coltman CA Jr, Hutton JJ. Reproducibility of the French-American-British classification of acute leukemia: the Southwest Oncology Group experience. Am J Hematol 1985; 18: 47-57.
13. Gehly GB, Bryant EM, Lee AM, Kidd PG, Thomas ED. Chimeric BCR-ABL messenger RNA as a marker for minimal residual disease in patients transplanted for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1991; 78: 458-465.
14. Radich JP, Kopecky KJ, Boldt DH, Head D, Slovak ML, Babu R, Lee A, Kessler P, Appelbaum F, Gehly C. Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction. Leukemia 1994; 8: 1688-1695.
15. Boldt DH, Kopecky KJ, Head D, Gehly C, Radich JP, Appelbaum FR. Expression of myeloid antigens by blast cells in acute lymphoblastic leukemia of adults. The Southwest Oncology Group experience. Leukemia 1994; 8: 2118-2126.
16. Minowada J, Ohnuma T, Moore GE. Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. J Natl Cancer Inst 1972; 49: 891-895.
17. Reid TW, Albert DM, Rabson AS, Russell P, Craft J, Chu EW, Tralka TS, Wilcox JL. Characteristics of an established cell line of retinoblastoma. J Natl Cancer Inst 1974; 53: 347-360.
18. American Type Culture Collection Catalogue of Cell Lines and Hybridomas. ATCC: Bethesda, MD, 1992, p 223.
19. Fogh J, Wright WC, Loveless JD. Absence of HeLa Cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst 1977; 58: 209-214.
20. Myers RM, Larin Z, Maniatis T. Detection of single base substitutions by ribonuclease cleavage at mismatches in RNA:DNA duplexes. Science 1985; 230: 1242-1246.
21. Winter E, Yamamoto F, Almohuera C, Perucho M. A method to detect and characterize point mutations in transcribed genes. Proc Natl Acad Sci USA 1985; 82: 7575-7579.
22. Ambion p53 genomic DNA screening module. Catalog No. 1610. Ambion, Austin, TX.
23. Wilcoxon F. Individual comparisons by ranking methods. Biometrics 1945; 1: 80.
24. Cox DR. Analysis of binary data. London: Chapman and Hall, 1970.
25. Cytel Software Corporation. Stat Xact user manual. Cytel Software Corporation: Cambridge, 1989.
26. Feinberg SE. The analysis of cross-classified categorical data. MIT Press: Cambridge, 1977.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
28. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. John Wiley: New York, 1980.
29. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-4878.
30. Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry? - revisited. J Pathol 1994; 172: 1-4.
31. INK4B, p53, and Rb genes in primary lymphoid malignancies. Blood 1996; 87: 4949-4958.
32. Corradini P, Inghirami G, Astolfi M, Ladetto M, Voena C, Ballerini P, Gu W, Nilsson K, Knowles DM, Boccadero M, Pileri A, Dalla-Favera R. Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia 1994; 8: 758-767.
33. Liu Y, Grander D, Soderhall S, Juliusson G, Gahrton G, Einhorn S. Retinoblastoma gene deletions in B-cell chronic lymphocytic leukemia. Genes Chromos Cancer 1992; 4: 250-256.
34. Stilgenbauer S, Dohner H, Bulgay-Morschel M, Weitz S, Bentz M, Lichter P. High frequency of monoallelic retinoblastoma gene deletion in B-cell chronic lymphoid leukemia shown by interphase cytogenetics. Blood 1993; 81: 2118-2124.
35. RB) in osteosarcomas and synovial sarcomas. Oncogene Res 1989; 1: 205-209.
36. Cheng J, Scully P, Shew J-Y, Lee W-H, Wila V, Haas M. Homozygous deletion of the retinoblastoma in an acute lymphoblastic leukemia (T) cell line. Blood 1990; 75: 730-735.
37. Sakai T, Ohtoni N, McGee TL, Robbins PD, Dryja TP. Oncogenic germ-line mutations in Sp1 and ATF sites in the human retinoblastoma gene. Nature 1991; 335: 83-86.
38. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, Dryja TP. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet 1991; 48: 880-888.
39. Ohtani-Fujita N, Fujita T, Aoike A, Osifchin NE, Robbins PD, Sakai T. CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. Oncogene 1993; 8: 1063-1067.
40. Wada M, Bartram CR, Nakamura H, Hachiya M, Chen D-L, Borenstein J, Miller CW, Ludwig L, Hansen-Hagge TE, Ludwig W-D, Reiter A, Mizoguchi H, Koeffler HP. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 1993; 82: 3163-3169.
41. Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Hirai H, Ishikawa F, Takaku F. Mutations of the p53 gene in lymphoid leukemia. Blood 1991; 77: 1153-1156.
42. Fenaux P, Jonveaux P, Quiquandon I, Preudhomme C, Lai JL, Vanrumbeke M, Loucheux-Lefebvre MH, Bauters F, Berger R, Kerckaert JP. Mutations of the p53 gene in B-cell lymphoblastic acute leukemia: a report on 60 cases. Leukemia 1992; 6: 42-46.
43. Felix CA, Nau MM, Takasashi T, Mitsudomi T, Chiba I, Poplak DG, Reamon GH, Cole DE, Letterio JJ, Whang-Peng J, Knutsen T, Minna JD. Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. J Clin Invest 1992; 89: 640-647.
44. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-330.
45. Almasan A, Yin Y, Kelly RE, Lee EY-HP, Bradley A, Li W, Bertino JR, Wahl GM. Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. Proc Natl Acad Sci USA 1995; 92: 5436-5440.